WallStreetZenWallStreetZen

NASDAQ: IKT
Inhibikase Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for IKT

Based on 5 analysts offering 12 month price targets for Inhibikase Therapeutics Inc

Min Forecast
$3.00+78.57%
Avg Forecast
$5.00+197.62%
Max Forecast
$8.00+376.19%

Should I buy or sell IKT stock?

Based on 5 analysts offering ratings for Inhibikase Therapeutics Inc.

Strong Buy
Strong Buy
4 analysts 80%
Buy
1 analysts 20%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although IKT's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates IKT as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their IKT stock forecasts and price targets.

IKT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-04
lockedlocked$00.00+00.00%2026-01-21
lockedlocked$00.00+00.00%2025-12-26
lockedlocked$00.00+00.00%2025-12-17
lockedlocked$00.00+00.00%2025-12-11

1 of 1

Forecast return on equity

Is IKT forecast to generate an efficient return?

Company
-42.88%
Industry
12.16%
Market
148.43%
IKT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is IKT forecast to generate an efficient return on assets?

Company
-40.92%
Industry
-6.19%
IKT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

IKT earnings per share forecast

What is IKT's earnings per share in the next 2 years based on estimates from 8 analysts?

Avg 1 year Forecast
-$0.54
Avg 2 year Forecast
-$0.56

IKT revenue forecast

What is IKT's revenue in the next 2 years based on estimates from 9 analysts?

Avg 1 year Forecast
$252.5k
Avg 2 year Forecast
$336.7k

IKT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
IKT$1.68$5.00+197.62%Strong Buy
ENLV$0.93$13.00+1,297.85%Strong Buy
SLGL$79.22$110.00+38.85%Buy
ARCT$7.72$18.29+136.87%Strong Buy
KROS$11.04$20.50+85.69%Buy
View Top Biotech Stocks

Inhibikase Therapeutics Stock Forecast FAQ

Is Inhibikase Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: IKT) stock is to Strong Buy IKT stock.

Out of 5 analysts, 4 (80%) are recommending IKT as a Strong Buy, 1 (20%) are recommending IKT as a Buy, 0 (0%) are recommending IKT as a Hold, 0 (0%) are recommending IKT as a Sell, and 0 (0%) are recommending IKT as a Strong Sell.

If you're new to stock investing, here's how to buy Inhibikase Therapeutics stock.

What is IKT's earnings growth forecast for 2026-2027?

(NASDAQ: IKT) Inhibikase Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 26.85%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 1,661.4%.

Inhibikase Therapeutics's earnings in 2026 is -$48,259,189.On average, 8 Wall Street analysts forecast IKT's earnings for 2026 to be -$71,059,965, with the lowest IKT earnings forecast at -$129,391,983, and the highest IKT earnings forecast at -$51,294,679.

In 2027, IKT is forecast to generate -$74,149,528 in earnings, with the lowest earnings forecast at -$129,391,983 and the highest earnings forecast at -$44,362,966.

What is IKT's revenue growth forecast for 2026-2027?

(NASDAQ: IKT) Inhibikase Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.83%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 27.62%.

Inhibikase Therapeutics's revenue in 2026 is $0.On average, 9 Wall Street analysts forecast IKT's revenue for 2026 to be $33,338,241, with the lowest IKT revenue forecast at $0, and the highest IKT revenue forecast at $277,268,536.

In 2027, IKT is forecast to generate $44,450,503 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $277,268,536.

What is IKT's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: IKT) forecast ROA is -40.92%, which is lower than the forecast US Biotechnology industry average of -6.19%.

What is IKT's Price Target?

According to 5 Wall Street analysts that have issued a 1 year IKT price target, the average IKT price target is $5.00, with the highest IKT stock price forecast at $8.00 and the lowest IKT stock price forecast at $3.00.

On average, Wall Street analysts predict that Inhibikase Therapeutics's share price could reach $5.00 by Mar 4, 2027. The average Inhibikase Therapeutics stock price prediction forecasts a potential upside of 197.62% from the current IKT share price of $1.68.

What is IKT's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: IKT) Inhibikase Therapeutics's current Earnings Per Share (EPS) is -$0.49. On average, analysts forecast that IKT's EPS will be -$0.54 for 2026, with the lowest EPS forecast at -$0.98, and the highest EPS forecast at -$0.39. In 2027, IKT's EPS is forecast to hit -$0.56 (min: -$0.98, max: -$0.34).

What is IKT's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: IKT) forecast ROE is -42.88%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.